

Tot Biopharm opens new biologics facility in Suzhou

22 June 2018 | News

With the new facility, Tot Biopharm will also be able to produce both biologic drugs and small molecular drugs at commercial scale.



Chinese bio-pharmaceutical developer, manufacturer and marketer of oncology drugs Tot Biopharm recently announced that its second phase project, a monoclonal antibodies (mAb) production site with 16,000L capacity, was inaugurated in Suzhou Industrial Park in May 2018.

The 13,000-square meter facility will be capable of meeting all-around demand from the biopharmaceutical sector for upstream research and development, pilot-scale production, clinical trial drugs production and commercial production.

With the new facility, Tot Biopharm will also be able to produce both biologic drugs and small molecular drugs at commercial scale.

The company has established an industry leading anti-tumor drug technology platform, developed multiple series and varieties of antitumor drugs and formed a high-quality product portfolio. The first phase of construction for the specialized cancer drug production base, including 500L-biologic pilot plant, OEL-5 isolator for ADC, BSL-2 certified viral facility, and small molecule plant (2 oral and 1 injectable plants), was completed in 2012.

The production capacity of mAbs is on track to be scaled up to 16,000L, making it one of the largest such facilities within China's biopharmaceutical industry. The factory is expected to provide high-quality yet affordable drugs to patients, acting to cut the country's medical costs while enhancing the global competitiveness.